13 November 2012
The identification of location of the production site of a new pharmaceutical company NovaMedica, a joint enterprise betweenthe Russian high-technology investment fund RUSNANO and the American venture healthcare fund Domain Associates will be chosen at the end of the first quarter of 2013.
12 November 2012
Fabrice Egros was appointed as COO, Pharmaceutical Director and board member of NovaMedica a novel Russian pharmaceutical company, which was established within the frameworks of the joint project between RUSNANO and the American venture fund Domain Associates.
Russian pharmaceutical company NovaMedica announces the opening of its US office
12 November 2012
NovaMedica, a company whose mission is commercializing highly innovative pharmaceutical products in Russia and the CIS, today announces the opening of its US office.
Special autumn session for the pharmaceutical business leaders
01 October 2012
Vladimir Gurdus: In order to foster the development of an innovative pharmaceuticals sector in Russia, we need the support of a globally competitive cluster of venture investors in the sector here in Russia.
Domain Associates & RUSNANO announce first joint investment
24 July 2012
Domain Associates, the Princeton, NJ- and San Diego, CA-based venture capital firm and RusnanoMedInvest (“RMI”, a subsidiary of RUSNANO) today announced their first investment under a joint agreement reached in March. The two will jointly invest nearly $40 million in San Diego, CA-based, CoDa Therapeutics, a Domain portfolio company, along with current investors GBS Ventures (Melbourne, Australia) and BioPacificVentures (Auckland, NZ).
St. Petersburg International Economic Forum
21 June 2012
Leonid Melamed: Isolated oases of narrowly focused innovation in life sciences are not the way forward for Russia and represent a temporary fix at best – what is needed to drive truly transformational change are fully-integrated life sciences innovation clusters supported by an ecosystem of research and development, finance and other key success factors and specialized skill sets
RUSNANO and Domain to Collaborate on Investments in Health Sciences Projects
06 March 2012
RUSNANO and Domain Associates, a U.S. venture capital firm specializing in leading-edge life sciences technologies, today announced a partnership that will spur modernization of the Russian healthcare market by bringing next-generation pharmaceuticals, medical devices and diagnostics to Russia.
NovaMedica will produce migraine drug Relonova in Moscow
23 March 2023
A resource for anti-tumor drugs testing has been launched in Russia
23 March 2023
Building a Community of Trust in Epilepsy & Rare Syndromes
23 March 2023
22 March 2023